Long-term toxicity of the treatment for germ cell-cancer. A review.

[1]  S. Fosså,et al.  Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953–2015: A population-based prospective cohort study , 2019, PloS one.

[2]  Q. Dong,et al.  Clinical characteristics of testicular seminoma in individuals in West China: a 10-year follow-up study , 2019, Cancer management and research.

[3]  C. Bouchardy,et al.  Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer , 2019, BMC Urology.

[4]  L. Fattore,et al.  c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells , 2019, International journal of molecular sciences.

[5]  K. Dieckmann,et al.  Is there still a place for retroperitoneal lymph node dissection in clinical stage 1 nonseminomatous testicular germ-cell tumours? A retrospective clinical study , 2018, BMC Urology.

[6]  L. Einhorn,et al.  Long-term toxicity of cisplatin in germ-cell tumor survivors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  E. Gamazon,et al.  Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer , 2017, Clinical Cancer Research.

[8]  S. Fosså,et al.  Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: A multicenter study of North American testicular cancer survivors (TCS). , 2017 .

[9]  J. Gietema,et al.  Life expectancy 20 years after cisplatin-based treatment for testicular cancer (TC). , 2017 .

[10]  S. Fosså,et al.  Clinical, sociodemographic, and behavioral factors associated with cumulative burden of morbidity (CBM) among testicular cancer survivors (TCS) in the Platinum study. , 2017 .

[11]  C. Earle,et al.  An evaluation of the breast cancer Well Follow-up Care Initiative using administrative databases: A new model of analysis. , 2017 .

[12]  P. Pedrazzoli,et al.  Incidence of secondary malignancies (SM) in patients (pts) with germ cell tumors (GCT) who received high-dose chemotherapy (HDCT): A retrospective study from the European Society for Blood and Marrow Transplantation (EBMT) database. , 2017 .

[13]  S. Fosså,et al.  Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Frisina,et al.  Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity , 2016, Clinical Cancer Research.

[15]  S. Fosså,et al.  Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Fosså,et al.  Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Smit,et al.  Early development of the metabolic syndrome after chemotherapy for testicular cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  K. Walker-Bone,et al.  Bleomycin-induced Raynaud's phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Fosså,et al.  Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Derick R. Peterson,et al.  Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Dieckmann,et al.  Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. , 2011, Anticancer research.

[22]  H. Boezen,et al.  Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Junshik Hong,et al.  Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis , 2011, Cancer Chemotherapy and Pharmacology.

[24]  P. Okunieff,et al.  Testicular cancer survivorship: research strategies and recommendations. , 2010, Journal of the National Cancer Institute.

[25]  K. Hemminki,et al.  Second cancers after testicular cancer diagnosed after 1980 in Sweden. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  D. Dearnaley,et al.  Long‐term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer , 2010, Cancer.

[27]  S. Fosså,et al.  Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors , 2009, Journal of the National Cancer Institute.

[28]  S. Fosså,et al.  Pulmonary function in long-term survivors of testicular cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  B. Yeap.  Testosterone and ill-health in aging men , 2009, Nature Clinical Practice Endocrinology &Metabolism.

[30]  Ingrid J Orre,et al.  Chronic cancer-related fatigue in long-term survivors of testicular cancer. , 2008, Journal of psychosomatic research.

[31]  H. Jürgens,et al.  Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin , 2008, The Pharmacogenomics Journal.

[32]  S. Fosså,et al.  Is the sexual function compromised in long-term testicular cancer survivors? , 2007, European urology.

[33]  M. Louwman,et al.  Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Hermann Brenner,et al.  Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. , 2007, The Lancet. Oncology.

[35]  H. B. Marsden,et al.  A study of soft tissue sarcomas after childhood cancer in Britain , 2007, British Journal of Cancer.

[36]  P. Hall,et al.  Noncancer causes of death in survivors of testicular cancer. , 2007, Journal of the National Cancer Institute.

[37]  R. Lothe,et al.  Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Logothetis,et al.  Review of late complications of treatment and late relapse in testicular cancer. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[39]  M. Loriot,et al.  Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy , 2006, Clinical Cancer Research.

[40]  C. Pui,et al.  Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. , 2006, Journal of the National Cancer Institute.

[41]  A. Smit,et al.  Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Fosså,et al.  Paternity following treatment for testicular cancer. , 2005, Journal of the National Cancer Institute.

[43]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[44]  John D Boice,et al.  Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. , 2005, Journal of the National Cancer Institute.

[45]  B. Pinto,et al.  Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  T. Wilsgaard,et al.  Blood pressure and body mass index in long-term survivors of testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Dearnaley,et al.  Fertility, gonadal and sexual function in survivors of testicular cancer , 2005, British Journal of Cancer.

[48]  A. Mykletun,et al.  Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  A. V. van Roon,et al.  Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. , 2004, European journal of cancer.

[50]  Andrew K. Lee,et al.  Mortality after cure of testicular seminoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  L. Niskanen,et al.  Sex hormones, inflammation and the metabolic syndrome: a population-based study. , 2003, European journal of endocrinology.

[52]  S. Fosså,et al.  The level of physical activity in long-term survivors of testicular cancer. , 2003, European journal of cancer.

[53]  D P Dearnaley,et al.  Cardiovascular disease as a long-term complication of treatment for testicular cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  S. Fosså,et al.  Fatigue, anxiety, and depression in long-term survivors of testicular cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  D. Vaughn,et al.  Long-Term Medical Care of Testicular Cancer Survivors , 2003, Annals of Internal Medicine.

[56]  S. Fosså,et al.  Long-term renal function after treatment for malignant germ-cell tumours. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  S. Sleijfer.  Bleomycin-induced pneumonitis. , 2001, Chest.

[58]  P. Hinds,et al.  NCCN Practice Guidelines for Cancer-Related Fatigue. , 2000, Oncology.

[59]  C. Bokemeyer,et al.  Sexual function and fertility after treatment of testicular cancer , 2000, Current opinion in urology.

[60]  D. Sleijfer,et al.  Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer , 2000, The Lancet.

[61]  B. Kohler,et al.  Risk of second malignant neoplasms among long-term survivors of testicular cancer. , 1997, Journal of the National Cancer Institute.

[62]  B. Stoffel‐Wagner,et al.  Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. , 1997, The Journal of urology.

[63]  S. Tretli,et al.  Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. , 1997, European journal of cancer.

[64]  C. Bokemeyer,et al.  Evaluation of long-term toxicity after chemotherapy for testicular cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  L. Einhorn,et al.  Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  W. Siegert,et al.  Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. , 1995, Journal of the National Cancer Institute.

[67]  L. Einhorn,et al.  Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. , 1993, Journal of the National Cancer Institute.

[68]  P. Sterk,et al.  Long-term effects of chemotherapy in patients with testicular cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  W. Trojaborg,et al.  Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  S. W. Hansen,et al.  Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  G. Bosl,et al.  Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  G. Bosl,et al.  Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. , 1981, Annals of internal medicine.

[73]  B. Mellado,et al.  Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients , 2017, Journal of the National Cancer Institute.

[74]  B. Wolffenbuttel,et al.  UROLOGICAL ONCOLOGY: TESTIS CANCER AND ADVANCES IN ONCOLOGICAL THERAPY The Metabolic Syndrome and Disturbances in Hormone Levels in Long-Term Survivors of Disseminated Testicular Cancer , 2005 .

[75]  D. Dearnaley,et al.  Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  G. Bleijenberg,et al.  Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. , 2002, European journal of cancer.

[77]  R. Motzer,et al.  Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. , 1998, The Journal of urology.

[78]  P. Tothill,et al.  The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. , 1992, European journal of cancer.